.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,453,510

« Back to Dashboard

Summary for Patent: 5,453,510

Title: Neuromuscular blocking agents
Abstract:1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockage), in comparison with the known mixture of geometrical and optical isomers.
Inventor(s): Hill; Derek A. (Dartford, GB2), Turner; Geoffrey L. (Dartford, GB2)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/911,887
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,453,510

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9015473Jul 13, 1990

International Patent Family for Patent: 5,453,510

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria138369<disabled in preview>
Australia1134695<disabled in preview>
Australia687481<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc